Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Teva's Cinqaero Gets Positive CHMP View, Decision In 2H16

Published 06/27/2016, 08:10 AM
Updated 07/09/2023, 06:31 AM
TEVA
-
AGN
-
PFE
-
AGN_pa
-
AMPH
-

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that Cinqaero (reslizumab), which is under review for use as an add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment, got a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

We note that Cinqaero gained FDA approval in late Mar 2016 where it was launched under the trade name Cinqair. With the CHMP issuing a positive opinion, we believe the candidate will gain EU approval, potentially in the second half of the year.

Teva has several programs ranging from phase I to registration stage in its pipeline with many of these focused on the central nervous system (CNS) and respiratory fields. As far as other therapeutic areas like women’s health and oncology are concerned, Teva is focusing on market-ready products or late-stage candidates to maximize sustainable profitability.

Meanwhile, Teva is looking to strengthen its generics business and is set to acquire Allergan (NYSE:AGN_pa) plc’s (NYSE:AGN) generics business for $40.5 billion. Once this deal closes, potentially by the end of this month, Teva will expand its presence as well as portfolio significantly.

Teva is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the medical sector include Pfizer, Inc. (NYSE:PFE) and Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) , both Zacks Rank #1 (Strong Buy) stocks.

PFIZER INC (PFE): Free Stock Analysis Report

ALLERGAN PLC (AGN): Free Stock Analysis Report

AMPHASTAR PHARM (AMPH): Free Stock Analysis Report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.